Background: Intravenous salbutamol (albuterol) reduces lung water in patients with the acute respiratory\ud distress syndrome (ARDS). Experimental data show that it also reduces pulmonary neutrophil accumulation or\ud activation and inflammation in ARDS.\ud Aim: To investigate the effects of salbutamol on neutrophil function.\ud Methods: The in vitro effects of salbutamol on neutrophil function were determined. Blood and\ud bronchoalveolar lavage (BAL) fluid were collected from 35 patients with acute lung injury (ALI)/ARDS, 14\ud patients at risk from ARDS and 7 ventilated controls at baseline and after 4 days’ treatment with placebo or\ud salbutamol (ALI/ARDS group). Alveolar–capillary permeability was measured in vivo by thermodilution\ud (PiCCO). Neutrophil activation, adhesion molecule expression and inflammatory cytokines were measured.\ud Results: In vitro, physiological concentrations of salbutamol had no effect on neutrophil chemotaxis, viability\ud or apoptosis. Patients with ALI/ARDS showed increased neutrophil activation and adhesion molecule\ud expression compared with at risk-patients and ventilated controls. There were associations between alveolar–\ud capillary permeability and BAL myeloperoxidase (r = 0.4, p = 0.038) and BAL interleukin 8 (r = 0.38,\ud p = 0.033). In patients with ALI/ARDS, salbutamol increased numbers of circulating neutrophils but had no\ud effect on alveolar neutrophils.\ud Conclusion: At the onset of ALI/ARDS, there is increased neutrophil recruitment and activation. Physiological\ud concentrations of salbutamol did not alter neutrophil chemotaxis, viability or apoptosis in vitro. In vivo,\ud salbutamol increased circulating neutrophils, but had no effect on alveolar neutrophils or on neutrophil\ud activation. These data suggest that the beneficial effects of salbutamol in reducing lung water are unrelated to\ud modulation of neutrophil-dependent inflammatory pathways
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.